Berlin. The Biontech vaccine has been used worldwide against the coronavirus for about a year and a half. It protects millions of people from serious COVID-19 diseases. Although many international studies have already proven this, opponents of vaccination continue to attack the drug.
Referring to a Biontech document from the USA, the manufacturer was recently accused of not being convinced by its vaccine at all.
Claim: “Biontech doesn’t even believe in vaccination itself,” says AfD, for example.
facts: The focus of the allegation against the Maines pharmaceutical company is its report to the US Securities and Exchange Commission (SEC) on March 30, 2022 for fiscal year 2021. Under US commercial law, such a report must be filed annually by foreign securities firms.
In principle, in this report Biontech refers to the “high level of protection” of vaccination. The agent provides “a high level of protection against critical variants, including alpha, beta and delta”. According to the company, the latest lab studies also showed that three doses of the vaccine were also effective against the Omicron variant.
But one sentence in particular in the 700-page newspaper raises people’s spirits. Biontech wrote: “We may not be able to demonstrate sufficient efficacy or safety for a Covid-19 vaccine and/or variant-specific compounds to warrant permanent regulatory approval in the United States, United Kingdom, European Union, or in other countries where the vaccine has been received emergency marketing authorization. or conditional.
Some conclude that even the manufacturer admits that it has put an ineffective and unsafe remedy on the market.
The stock exchange supervisory body sets precise regulations
But this is not true. The statement was made in a cautionary statement regarding forward-looking statements. This legal information is specified in detail by the supervisory authority of the exchange in order to avoid possible claims for damages by investors.
In the Biontech report, this regulation means that all conceivable effects on company profits and business development must be described. This should enable investors to get an idea of all the potential risks.
Listed potential uncertainties include, but are not limited to, competition from other vaccines, their efficacy, cost, shipping and storage options, safety, side effects, and sustainability of the immune response. Business results can also be affected by, for example, “how necessary a Covid-19 vaccine will remain in the future”.
The Biontech Comirnaty vaccine is currently subject to conditional market approval in the European Union. This was first granted in December 2020 and extended for another year in November 2021.
How did Kommernati perform in studies?
The European Medicines Agency (EMA) places the same requirements on the safety of Covid-19 vaccines as any other vaccine approved in the European Union. With conditional consent, data is evaluated as soon as it is available – not when all investigations have been completed.
After initial emergency approval in the United States, the Food and Drug Administration had already granted full approval for the drug in August 2021.
According to the current scientific state, Comirnaty is approximately 90 percent effective against severe Covid 19 disease when infected with the delta variant. According to the Robert Koch Institute, preliminary data show that the protection of the omicron mutant is of lower quality.
In a Pfizer-funded study, the effectiveness of three doses against hospitalization of Omicron was 85 percent within the first three months after vaccination. But it dropped to 55 percent after three months or more. At no time during the pandemic, famous researchers have claimed that the corona vaccination protects 100% of Covid-19.
All information about dpa data validations
dpa data validation team contact page
© dpa-infocom, dpa: 220509-99-211871/2